RxDoctor Payments Data

Angela Beckel

Nurse Practitioner · Des Moines, IANPI 1881874436

Payments from drug & device makers

$1,620in general payments, 2019–2025

Across 26 payments — averaging $62.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$747
  • Verona Pharma, Inc.$521
  • Amgen$162
  • AstraZeneca$87
  • Insmed, Inc.$47
  • Baxter Healthcare$24
  • plus $33 from 2 others

What the payments were for

  • Consulting fees$47529%
  • Speaking & faculty fees$18011%
  • Food & beverage$96560%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,620 in reported general payments places this provider in the 90th percentile of 1,346 nurse practitioner providers in Iowa.

See all nurse practitioner providers in Iowa

Medicare billing

Part B allowed, 2024
$26,119
Medicare patients
186
Services billed
504

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter286$201,239
Spiriva RespimatTiotropium Bromide325$179,724
OfevNintedanib Esylate14$170,229
Breztri AerosphereBudesonide/Glycopyr/Formoterol141$102,171
Breo ElliptaFluticasone/Vilanterol178$82,709
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr162$81,892
Incruse ElliptaUmeclidinium Bromide201$76,759
Advair HfaFluticasone Propion/Salmeterol200$75,948
Stiolto RespimatTiotropium Br/Olodaterol Hcl131$74,258
SymbicortBudesonide/Formoterol Fumarate192$50,680
Dupixent SyringeDupilumab13$48,435
Dupixent PenDupilumab12$44,904
Arnuity ElliptaFluticasone Furoate75$27,624
Combivent RespimatIpratropium/Albuterol Sulfate42$26,143
DuleraMometasone/Formoterol66$24,235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimSpiriva Respimat, Ofev, Stiolto Respimat, Combivent Respimat$747$450,353512 claims
AstraZenecaBreztri Aerosphere, Symbicort$87$152,851333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,346 nurse practitioner providers in Iowa.

Other nurse practitioner in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →